1 research outputs found
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials
At a meeting of the EU/US/Clinical Trials in Alzheimer’s Disease (CTAD) Task Force in
December 2016, an international group of investigators from industry, academia, and regulatory
agencies reviewed lessons learned from ongoing and planned prevention trials, which will help
guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force
discussed challenges that need to be addressed across all aspects of clinical trials, calling for
innovation in recruitment and retention, infrastructure development, and the selection of outcome
measures. While cognitive change provides a marker of disease progression across the disease
continuum, there remains a need to identify the optimal assessment tools that provide clinically
meaningful endpoints. Patient- and informant-reported assessments of cognition and function may
be useful but present additional challenges. Imaging and other biomarkers are also essential to
maximize the efficiency of and the information learned from clinical trials